Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals has demonstrated strong revenue growth, with 4Q25 worldwide revenue for IMCIVREE totaling $57 million, reflecting approximately a 10% increase in the patient population under reimbursed therapy, indicating robust demand. The company's earnings projections for 2026 have been revised upwards to $293 million, primarily driven by an increased revenue ramp for the Bardet-Biedl syndrome (BBS) indication, which is expected to contribute significantly to overall sales. Additionally, the potential expansion of IMCIVREE into a total addressable market of approximately 27,000 new patients, along with limited competition and no approved therapies for this segment, positions the company for revenue growth that could exceed $2 billion by 2030.

Rhythm Pharmaceuticals faces significant risks that could adversely affect its financial outlook, primarily stemming from the potential inability to secure regulatory approval for setmelanotide beyond its currently approved indications. Additionally, the company may encounter setbacks with its earlier-stage candidates, which could hinder its efforts to broaden market coverage and enhance product convenience. A slower than anticipated sales ramp for IMCIVREE, combined with concerns about a limited patient population and possible dilution risk, further compounds the challenges to Rhythm's commercial success in the biopharmaceutical space.